BioCentury

7:00 AM GMT, Aug 1, 2005
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Spawning success

More than a decade after DNA vaccines emerged as a novel therapeutic genre, two such products have received marketing approval just days apart, albeit for disease prevention in horses and salmon. Vical Inc., which out-licensed the salmon product, believes the approval validates its technology and is looking to build on its argument with a Phase II proof-of-concept trial of a bivalent vaccine to treat cytomegalovirus infection

Read the full 669 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.